Home
Loading

aVenture is in Alpha: During this preview period, you should expect the research data to be limited and may not yet meet our exacting standards. We've made the decision to provide early access to our data to showcase the product as we build, but you should not yet rely upon it alone for your investment decisions.

aVenture is in Alpha: During this preview period, you should expect the research data to be limited and may not yet meet our exacting standards. We've made the decision to provide early access to our data to showcase the product as we build, but you should not yet rely upon it alone for your investment decisions.

Get in touch

  • Contact

  • Request a demo

  • Request data updates

  • Add a company

Research

  • Companies

  • Investors

  • People

aVenture

  • Sitemap

  • Feature requests

Member

Backed by

© aVenture Investment Company, 2026. All rights reserved.

San Francisco, CA, USA

Privacy Policy

aVenture Investment Company ("aVenture") is an independent research platform providing detailed analysis and data on startups, venture capital investments, and key industry individuals. It is not a registered investment adviser, broker-dealer, or investment advisor and does not provide investment advice or recommendations. The data provided by aVenture does not constitute recommendations or advice, whether by methodology, analysis, AI-generated content, or a statement written by a staff member of aVenture.

aVenture is not affiliated with any of the people, companies, organizations, government agencies, regulatory bodies, or investment funds we provide coverage for on this site unless explicitly stated otherwise. Users assume full responsibility for decisions made based on information obtained from this platform. Links to external websites do not imply endorsement or affiliation with aVenture. Any links that provide the ability to invest in a primary or secondary transaction in a company are for convenience only and do not constitute solicitations or offers to buy or sell an investment. Investors should exercise heightened precaution and due diligence when investing in private companies, especially those not independently audited.

While we strive to provide valuable insights with objectivity and professional diligence, we cannot guarantee the accuracy of the information provided on our platform. Before making any investment decisions, you should verify the accuracy of all pertinent details for your decision. To the fullest extent permitted by law, aVenture shall not be liable for any direct, indirect, incidental, consequential, or financial damages arising from use of this site, whether by consumers of its contents directly or by persons or organizations covered by our research, even if we are advised of the possibility. Our best-efforts processes and correction request forms do not create a warranty or duty of care.

Profiles on this platform may include content generated in part by large language models (LLMs, artificial intelligence) that aggregate publicly available sources (e.g., SEC EDGAR, public filings, press releases). Source attribution is provided where known; always verify statements and claims here against original sources before relying on any data. Content on our site may contain inaccuracies, omissions, or what are commonly called 'hallucinations' if generated in part or in full by AI / LLMs. The risk can also exist even when content is written by a human, as internal and third-party sources may also have inaccuracies for the same or different reasons. While we randomly audit a proportion of content, this is not exhaustive.

We recommend that an independent auditor be hired to verify the accuracy of the information before relying on it for any sensitive decisions. By accessing this platform, you agree not to rely solely on any information generated by AI, aggregated, or sourced or written otherwise on this site, for investment, financial, or other decisions. aVenture assumes no responsibility for inaccuracies, omissions, or hallucinations. You must independently verify all data from primary sources. Use of this platform constitutes your waiver of claims for reliance-based damages, including negligent misrepresentation. To report an error, request a correction, or dispute information about a company or individual, contact us via our request data updates form.

Loading homepage
Loading
Home›Research›Companies

Companies

Loading
Home›
Research›
Companies›
Mekonos
AddedFeb 17, 2024
UpdatedJun 18, 2026
Mekonos

Mekonos

Mekonos, a Silicon Valley venture-backed firm, pioneers in scalable cell-engineering tech for drug discovery.

HQ
San Francisco, CA, US
Founded
2017
Overview
Compare
Fundraising
Employees
Website

Mekonos, founded in Silicon Valley, is a venture-backed technology company focused on revolutionizing cell engineering. Their core mission is to make personalized medicine accessible through a proprietary platform that leverages scalable silicon technology. This platform enables precise delivery of multiplexed cargo into fragile cells, supporting partners in drug discovery and development. Mekonos aims to transform the medical landscape by providing advanced solutions for cell therapies.

Notable affiliates include key figures from the biotech and tech industries, contributing to Mekonos' innovative edge. The company has attracted significant venture capital investment, underscoring confidence in its technology and vision. Mekonos' achievements include developing a cutting-edge cell-engineering platform that promises to enhance drug discovery processes and personalized medicine. Their impact is marked by advancing the precision and scalability of cell therapies, positioning them as a leader in the biotech sector.

Mekonos - Similar Companies

Encellin logo

Encellin

encellin.com

Spheringenics logo

Spheringenics

Mytos logo

Mytos

mytos.bio

Cell BioEngines logo

Cell BioEngines

cellbioengines.com

Scaled Biolabs logo

Scaled Biolabs

scaledbiolabs.com

Cellanome logo

Cellanome

cellanome.com

Celldom logo

Celldom

celldom.com

CellChorus logo

CellChorus

cellchorus.com

Mechano-Therapeutics logo

Mechano-Therapeutics

CellFE logo

CellFE

Antheia logo

Antheia

antheia.bio

Altos Labs logo

Altos Labs

altoslabs.com

Makucell logo

Makucell

makucellinc.com

Ontera logo

Ontera

ontera.bio

Convalesce logo

Convalesce

convalesce.co

Mekonos - Quick Facts

Who are Mekonos' competitors?

Companies similar to Mekonos include Encellin, Spheringenics, Mytos and Cell BioEngines.

When was Mekonos founded?

Mekonos was founded in 2017.

Where is Mekonos' headquarters located?

Mekonos' headquarters is located in San Francisco, CA, US.

When was Mekonos' last funding round?

Mekonos' most recent funding round was for $25M (USD) in November 2021.

How much has Mekonos raised to-date?

As of Nov 9, 2021, Mekonos has raised a total of $31M (USD).

How many employees does Mekonos have?

Mekonos has 30 employees as of Feb 5, 2024.

Mekonos - Classification

Industry
  • Hardware
Ownership
  • Venture Capital
Technology
  • Biotech
Geographic Exposure
  • Global
Revenue
  • Recurring
Customer
  • Enterprise
Main Product
  • Cell Engineering
Tags
  • Platform
NAICS
  • 513200Software Publishers
  • 510000Information
  • 513000Publishing Industries
  • 513210Software Publishers
SIC
  • 7300Business Services
  • 7370Computer Programming, Data Processing, And Other Computer Related
  • 7372Prepackaged Software
Show 6 more industry codes
NAICS
  • 540000Professional, Scientific, and Technical Services
  • 541500Computer Systems Design and Related Services
  • 541000Professional, Scientific, and Technical Services
  • 541510Computer Systems Design and Related Services
  • 541511Custom Computer Programming Services
SIC
  • 7371Computer Programming Services